The R enantiomer of NVP-HDM201 is primarily investigated for its potential in cancer therapy, particularly in targeting p53-related pathways. It functions as a selective inhibitor of MDM2, a protein that negatively regulates the tumor suppressor p53. By inhibiting MDM2, this compound helps restore p53 activity, promoting apoptosis in cancer cells and inhibiting tumor growth. Its application is especially relevant in cancers where p53 is wild-type but suppressed by MDM2 overexpression, such as certain types of sarcomas, leukemias, and solid tumors. Research is ongoing to explore its efficacy in combination therapies and its potential to overcome resistance to conventional treatments.